At the time of writing, Ascendis Pharma A/S ADR [ASND] stock is trading at $175.69, up 7.89%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ASND shares have gain 8.45% over the last week, with a monthly amount glided 4.91%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ascendis Pharma A/S ADR [NASDAQ: ASND] stock has seen the most recent analyst activity on May 05, 2025, when Morgan Stanley upgraded its rating to a Overweight but kept the price target unchanged to $250 for it. Previously, RBC Capital Mkts started tracking the stock with Outperform rating on April 16, 2025, and set its price target to $205. On January 07, 2025, UBS initiated with a Buy rating and assigned a price target of $196 on the stock. Oppenheimer upgraded its rating to a Outperform but stick to its price target of $180 on September 05, 2024. TD Cowen upgraded its rating to a Buy and raised its price target to $175 on June 25, 2024. Stifel started tracking with a Buy rating for this stock on May 31, 2024, and assigned it a price target of $200. In a note dated December 20, 2023, Jefferies initiated an Buy rating and provided a target price of $150 on this stock.
For the past year, the stock price of Ascendis Pharma A/S ADR fluctuated between $111.09 and $183.00. Currently, Wall Street analysts expect the stock to reach $180 within the next 12 months. Ascendis Pharma A/S ADR [NASDAQ: ASND] shares were valued at $175.69 at the most recent close of the market. An investor can expect a potential return of 2.45% based on the average ASND price forecast.
Analyzing the ASND fundamentals
According to Ascendis Pharma A/S ADR [NASDAQ:ASND], the company’s sales were 394.05M for trailing twelve months, which represents an 2.09% jump. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -0.91%, Pretax Profit Margin comes in at -0.92%, and Net Profit Margin reading is -0.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is 1.91 and Total Capital is -1.9. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-4.46.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 167.83 points at the first support level, and at 159.96 for the second support level. However, for the 1st resistance point, the stock is sitting at 180.75, and for the 2nd resistance point, it is at 185.80.
Ratios To Look Out For
It is important to note that Ascendis Pharma A/S ADR [NASDAQ:ASND] has a current ratio of 1.04. Also, the Quick Ratio is 0.71, while the Cash Ratio stands at 0.58. Considering the valuation of this stock, the price to sales ratio is 26.92.
Transactions by insiders
Recent insider trading involved Shu Aimee, Officer, that happened on May 12 ’25 when 2018.0 shares were purchased. Officer, JENSEN FLEMMING STEEN completed a deal on May 07 ’25 to buy 10938.0 shares. Meanwhile, Officer Shu Aimee bought 4204.0 shares on May 06 ’25.
